Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05517447 · ClinicalTrials.gov registry record · Phase 3
Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
A Phase 3 study of Thyroid Eye Disease, sponsored by Immunovant Sciences.
- Active
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT05517447: Active Phase 3 study of Thyroid Eye Disease, sponsored by Immunovant Sciences.
NCT05517447 is a Phase 3 study of Thyroid Eye Disease that is active but no longer recruiting, run by Immunovant Sciences. The registered enrollment target is 180 participants, above the 94-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (91% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05517447, a Phase 3 study of Thyroid Eye Disease, is active but no longer recruiting, sponsored by Immunovant Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a 2-cohort (observational and treatment cohort) extension study for participants completing feeder studies (IMVT-1401-3201 or IMVT-1401-3202). The observational cohort will assess the durability of proptosis response of feeder studies off treatment. The treatment cohort will evaluate the efficacy of batoclimab as assessed by proptosis responder rate.
Conditions Studied
Interventions
- OTHER Observational cohort study
- DRUG Batoclimab
Study Locations (20)
Other
- Site Number - 7565 - Sydney
- Site Number - 4671 - Bruges
- Site Number - 4672 - Brussels
- Site Number - 4673 - Brussels
- Site Number - 4670 - Ghent
- Site Number - 3454 - Tbilisi
- Site Number - 3455 - Tbilisi
- Site Number - 3450 - Tbilisi
- Site Number - 3451 - Tbilisi
- Site Number - 7550 - Budapest
- Site Number - 7552 - Pécs
Texas
- Site Number - 1508 - Houston
- Site Number - 1558 - Mesquite
California
- Site Number - 1520 - Glendora
Colorado
- Site Number - 1501 - Aurora
Michigan
- Site Number - 1526 - Livonia
Minnesota
- Site Number - 1513 - Rochester
Nevada
- Site Number - 1540 - Las Vegas
West Virginia
- Site Number - 1511 - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2022-11-06 |
| Est. Completion | 2026-08 |
| Phase | Phase 3 |
What the registry record for NCT05517447 still lists
NCT05517447 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 94-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (91% higher).
The record links to 1 condition, with Thyroid Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which Observational cohort study is the first listed.
NCT05517447 names 20 study sites across 9 states, led by Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT05517447 about?
NCT05517447 is a clinical study titled "Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease". This is a 2-cohort (observational and treatment cohort) extension study for participants completing feeder studies (IMVT-1401-3201 or IMVT-1401-3202). The observational cohort will assess the durability of proptosis response of feeder studies off treatment. The treatment cohort will evaluate the eff...
What is the current status of trial NCT05517447?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2022-11-06. Estimated completion is 2026-08.
What conditions does trial NCT05517447 study?
This clinical trial studies the following conditions: Thyroid Eye Disease.
What interventions are being tested in trial NCT05517447?
The interventions under investigation include: Observational cohort study (OTHER), Batoclimab (DRUG).
Who is sponsoring clinical trial NCT05517447?
This trial is sponsored by Immunovant Sciences, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05517447 being conducted?
This trial has 20 study locations across California, Colorado, Michigan, Minnesota, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05517447's enrollment target sits among peer trials
180 2nd of 15 the highest of 15 other Thyroid Eye Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Eye Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI